31-Oct-2018 13:51 EDT

Which Pharma Company Ratings Could Be At Risk If U.S. Drug Pricing Reforms Become Law?

Note: This article is only available for direct purchase or through our premium products

PREMIUM RESEARCH FROM RATINGSDIRECT

Premium Access

Purchase Article

Purchase this document or browse additional S&P Global Ratings' research. Per-article purchases are managed by Alacra. Your credit card statement will list Alacra as the sales agent.

RatingsDirect®

View this content, and all credit ratings content, on RatingsDirect®, the official desktop source for S&P Global Ratings. Your resource for efficient credit analysis.Learn More

RatingsDirect subscriber login Request a demo